On Aug. 13, a panel of the U.S. Court of Appeals for the Ninth Circuit issued an opinion in a securities fraud class action, Khoja v. Orexigen Therapeutics, No. 16-56069 2018 U.S. App. LEXIS 22371 (9th Cir. Aug. 13, 2018),...more
9/6/2018
/ Appeals ,
Class Action ,
Federal Rule 12(b)(6) ,
Form 10-Q ,
Form 8-K ,
Incorporation by Reference ,
Motion to Dismiss ,
Pharmaceutical Industry ,
Pleading Standards ,
PSLRA ,
Reversal ,
Securities Fraud ,
Securities Litigation
On June 25, 2014, the U.S. Supreme Court decided Halliburton Co. v. Erica P. John Fund, No. 13-317, __ U.S. __ (2014), slip op. (U.S. June 23, 2014) (Halliburton II), holding that defendants in a class action securities...more